Evidence map›Paper›PMID 36658128›Full record

ArticleNature communications2023

Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19.

Kara W Chew, Carlee Moser, Eric S Daar, David A Wohl, Jonathan Z Li, Robert W Coombs, Justin Ritz, Mark Giganti, Arzhang Cyrus Javan, Yijia Li and 16 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

26 authors.

Kara W ChewDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA. kchew@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-4865-4348
Carlee MoserHarvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0001-5601-9112
Eric S DaarLundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, USA.
David A WohlDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-7764-0212
Jonathan Z LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9914-9662
Robert W CoombsDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2709-0512
Justin RitzHarvard T.H. Chan School of Public Health, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6307-4849
Mark GigantiHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Arzhang Cyrus JavanNational Institutes of Health, Bethesda, MD, USA.
Yijia LiDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Manish C ChoudharyDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Rinki DeoDepartment of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Carlos MalvestuttoOhio State University Wexner Medical Center, Columbus, OH, USA.
Paul KlekotkaEli Lilly and Company, San Diego, CA, USA.
Karen PriceEli Lilly and Company, San Diego, CA, USA.
Ajay NirulaEli Lilly and Company, San Diego, CA, USA.
William FischerDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.
Veenu BalaUNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.
Ruy M RibeiroTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-3988-8241
Alan S PerelsonTheoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, USA.ORCID http://orcid.org/0000-0002-2455-0002
Courtney V FletcherUNMC Center for Drug Discovery, University of Nebraska Medical Center, Omaha, NE, USA.ORCID http://orcid.org/0000-0002-3703-7849
Joseph J EronDepartment of Medicine, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-4938-0644
Judith S CurrierDepartment of Medicine, David Geffen School of Medicine at University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0003-4279-4737
ACTIV-2/A5401 Study Team
Michael D HughesHarvard T.H. Chan School of Public Health, Boston, MA, USA.
Davey M SmithDepartment of Medicine, University of California, San Diego, La Jolla, CA, USA.ORCID http://orcid.org/0000-0003-3603-1733

Funding

UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
UCLA AIDS Prevention and Treatment Clinical Trials UnitU01AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CURRIER, JUDITH S. · 2007 to 2011
$13.9M
NIAID NIH HHS U01 AI069424NIAID NIH HHS UM1 AI069424
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36658128
PMCPMC9851732

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.